FDA
-
-
-
-
-
-
-
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Coherus BioSciences Reports Second Quarter 2024 Financial ResultsĀ and Provides Business Update
-
-
-
-
-
-
-
Midday movers: Tesla, Coinbase, and more
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
-
-
-
-
-
-
-
Coherus (CHRS) to Acquire Surface Oncology (SURF)
-
-
-
-
-
-
-
Coherus (CHRS) and Junshi Report Positive Final Overall Survival Results of JUPITER-02
-
-
-
-
-
-
-
Coherus (CHRS) and Junshi Have not Received Action Letter from FDA on toripalimab in combination with chemotherapy
-
323,579 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

